Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
8
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
2
users have commented on this narrative
18
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
15
users have liked this narrative
4
users have commented on this narrative
16
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Creo Medical Group
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
Key Takeaways Adoption of Creo's technology faces hurdles from slow hospital procurement, budget pressures, and delayed integration of clinical evidence, restricting near-term revenue growth. Expansion is challenged by geopolitical risks, competitive medtech landscape, and potential margin pressures from ongoing high R&D spend and formidable incumbents.
View narrative
UK£0.40
FV
65.6% undervalued
intrinsic discount
64.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
IMI
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Automation And Net Zero Will Transform Future Infrastructure
Key Takeaways Industry trends toward automation, energy efficiency, and smart products are driving IMI's margin expansion and recurring revenue growth. Disciplined capital allocation, targeted acquisitions, and operational efficiencies are supporting sustained earnings growth and future capital returns.
View narrative
UK£24.03
FV
3.6% undervalued
intrinsic discount
4.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
6 days ago
author updated this narrative
MaxLinear
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
5G Wireless And Data Center Demand Will Transform Connectivity Markets
Key Takeaways Expanding partnerships with major telecom and cloud customers, plus strong design wins in data center and wireless, position MaxLinear for sustained, broad-based growth. Ongoing innovation and cost efficiency in advanced connectivity and AI-focused solutions bolster the company's pricing power, profit margins, and market reach.
View narrative
US$19.85
FV
27.7% undervalued
intrinsic discount
18.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
5 days ago
author updated this narrative
Outset Medical
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Aging Demographics Will Drive Tablo Home Dialysis Adoption
Key Takeaways Rapid adoption of Tablo and strategic partnerships position Outset Medical for faster recurring revenue growth, accelerating market share gains and long-term profitability. Demographic trends and expanding home care markets offer lasting tailwinds, boosting recurring revenue potential and reinforcing Outset Medical's status as a leading dialysis innovator.
View narrative
US$39.00
FV
65.8% undervalued
intrinsic discount
13.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Ascendis Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
Pipeline Progress And Global Launches Will Expand Market Reach
Key Takeaways Strong product adoption, expanding indications, and pipeline advances support robust, recurring revenue growth and reduce concentration risks. Alignment with healthcare trends and increasing global disease prevalence drives broader market penetration, supporting long-term revenue and margin expansion.
View narrative
US$250.08
FV
22.2% undervalued
intrinsic discount
63.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
6 days ago
author updated this narrative
Beachbody Company
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Digital Retail And Health Trends Will Unlock New Demand
Key Takeaways Shift from MLM to omnichannel retail and digital integration positions Beachbody for strong revenue growth and high customer engagement across brands and channels. Operational efficiencies and tech-driven personalization boost margins, customer retention, and recurring digital subscription revenue, outpacing market expectations.
View narrative
US$13.00
FV
59.1% undervalued
intrinsic discount
-17.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
CareCloud
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
AI And Integrated Cloud Solutions Will Reshape Care Delivery
Key Takeaways Accelerating adoption of CareCloud's AI-driven, cloud-based solutions and expansion into new markets are driving higher-than-expected, sustainable revenue and margin growth. Proprietary data assets and first-mover advantage enable competitive differentiation, recurring high-margin SaaS revenue, and potential for new business lines through advanced AI-powered offerings.
View narrative
US$6.00
FV
54.7% undervalued
intrinsic discount
6.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Modulight Oyj
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Laser Therapies Will Expand Precision Care For Aging Global Markets
Key Takeaways Expanded therapy indications, unique integration, and U.S. expansion could enable outsized market share capture and accelerate recurring revenue growth. Strategic partnerships and proprietary AI-driven devices position Modulight for premium pricing, income diversification, and sustained margin expansion.
View narrative
€2.20
FV
43.8% undervalued
intrinsic discount
41.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
BHIA
Grupo Casas Bahia
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Digitalization And Latin America Demand Will Drive Expansion
Key Takeaways Accelerated transformation, digitalization, and strategic financial backing position Grupo Casas Bahia for stronger margins, earnings growth, and superior operational efficiency over peers. Expanding omnichannel credit and consolidating specialty retail deepen market leadership, drive higher sales, and capitalize on rising middle-class consumption in Brazil.
View narrative
R$7.93
FV
64.3% undervalued
intrinsic discount
5.83%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies